Medicine and Dentistry
Prognostic Factor
100%
Sarcoma
99%
Soft Tissue Sarcoma
98%
Cohort Analysis
89%
Overall Survival
89%
Malignant Neoplasm
80%
Neoplasm
70%
Biological Marker
68%
Osteosarcoma
62%
Lung Cancer
61%
Disease
58%
Hazard Ratio
44%
Lymphocyte
42%
Retrospective Study
39%
Small Cell Lung Cancer
38%
Recurrent Disease
37%
Neutrophil
36%
Gastrointestinal Stromal Tumor
36%
Systematic Review
36%
Non Small Cell Lung Cancer
31%
Radiation Therapy
28%
Connective Tissue Cancer
27%
Neck
27%
Meta-Analysis
26%
Hypoxia
24%
Hyponatremia
24%
Breast Sarcoma
24%
Bone Tissue
24%
Solitary Fibrous Tumor
24%
Circulating Tumor DNA
24%
Cancer Therapy
20%
C Reactive Protein
20%
COVID-19
19%
Chondrosarcoma
19%
Progression Free Survival
18%
Platelet
16%
Proportional Hazards Model
16%
Nodular Melanoma
14%
Formaldehyde
14%
Metastatic Melanoma
13%
Targeted Therapy
13%
Disease Specific Survival
13%
Oncology
12%
Proton Therapy
12%
Rhabdomyosarcoma
12%
Paraganglioma
12%
Neuropathic Pain
12%
Stereotactic Body Radiation Therapy
12%
Cancer Incidence
12%
Cross Sectional Study
12%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
71%
Biological Marker
71%
Sarcoma
65%
Neoplasm
55%
Overall Survival
54%
Cohort Study
53%
Comorbidity
52%
Soft Tissue Sarcoma
49%
Osteosarcoma
40%
Disease
39%
Gastrointestinal Stromal Tumor
36%
Circulating Tumor DNA
36%
Retrospective Study
28%
Melanoma
26%
Recurrent Disease
26%
Lung Cancer
25%
Hyponatremia
24%
Breast Sarcoma
24%
Solitary Fibrous Tumor
24%
Non Small Cell Lung Cancer
21%
C Reactive Protein
19%
Cytokine
19%
Chondrosarcoma
18%
Progression Free Survival
16%
Metastatic Melanoma
15%
Disease Exacerbation
15%
Rhabdomyosarcoma
12%
Second Cancer
12%
Cancer Susceptibility
12%
SARS Coronavirus
12%
Programmed Death 1 Receptor
12%
Cancer Incidence
12%
Pazopanib
12%
Ipilimumab
12%
Sodium
12%
Paraganglioma
12%
Imatinib
12%
Programmed Death 1 Ligand 1
12%
Neuropathic Pain
12%
Neuroendocrine Carcinoma
12%
Infection
12%
Nivolumab
12%
Inflammation
12%
Chemoradiation Therapy
12%
Pandemic
12%
Cross-Sectional Study
12%
Hemangioendothelioma
12%
Immunotherapy
12%
Small Cell Lung Cancer
11%
Tumor Necrosis Factor
7%